NIH seeks a senior executive-level drug development advisor to serve on an oversight committee for biologics research, from November 2026 for three years with options. Reserved for small businesses; full details are in the statement of work attachment.
COMBINED SYNOPSIS / SOLICITATION (COMPETITIVE) Title: Senior Advisor 2 for Biological Therapeutics Development to act as External Oversight Committee (EOC) Subject Matter Expert (SME) Services. (i) This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with RFO Part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. The solicitation number is 7571PSQ00013 issued as a Request for Quote for Senior Advisor 2 [subject matter expert (SME) services] in support of NIH Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) drug discovery and development programs and the associated BPN-Biologics External Oversight Committee. The Government reserves the right to make one award, multiple awards, or no awards as a result of this solicitation. This acquisition is set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (ii) This requirement is for the following services: The purpose of this requirement is to procure Senior Advisor 2 [subject matter expert (SME) services] in support of NIH Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) drug discovery and development programs and the associated BPN-Biologics External Oversight Committee. (iii) Description of requirement: NINDS is seeking to procure a highly experienced executive-level, drug discovery and development Senior Advisor 2 with extensive expertise in drug discovery and development, in support of the NIH HEAL Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. See Attachment #1 - Statement of Work (SOW) for more information. (iv) The Government anticipates award of a Fixed Price purchase order for this acquisition, and the anticipated base period of performance is: Base: 11/5/2026 � 11/4/2027 Option Year 1: 11/5/2027 � 11/4/2028 Option Year 2: 11/5/2028 � 11/4/2029 (v) The provisions at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at …
Yia | Contract Alerts reads every new notice and emails you the matches for your NAICS codes, location and certifications, each with a fit score. 14-day free trial.
Start free